Although speculative, it is conceivable that the residual IL2Rαβγ binding allowed by NKTR-214 activates protective Tregs in the peripheral blood where the CD8/Treg ratio is ~40-fold lower than that observed in the tumor [16]. This evidence concerns the gene NKTR and neoplasm.